---
title: "CMS grants NTAP reimbursement status for Abeona gene therapy ZEVASKYN under FY2027 IPPS rule"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294816144.md"
description: "CMS granted New Technology Add-On Payment (NTAP) status for Abeona Therapeutics' gene therapy ZEVASKYN under the FY2027 IPPS final rule. This status provides supplemental Medicare reimbursement above standard inpatient payments, supporting patient access. The decision complements ZEVASKYN’s permanent J-code, strengthening coverage for Medicare patients with qualifying disabilities."
datetime: "2026-08-04T11:32:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294816144.md)
  - [en](https://longbridge.com/en/news/294816144.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294816144.md)
generator: "portal-rs"
---

# CMS grants NTAP reimbursement status for Abeona gene therapy ZEVASKYN under FY2027 IPPS rule

-   CMS granted New Technology Add-On Payment status for ZEVASKYN under the FY2027 Hospital Inpatient Prospective Payment System final rule. \* NTAP provides supplemental Medicare reimbursement above standard hospital inpatient payments, supporting access to the gene therapy in eligible cases. \* Decision strengthens Medicare reimbursement alongside ZEVASKYN’s permanent J-code, supporting coverage for Medicare patients, including those with qualifying disabilities. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abeona Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040730PRIMZONEFULLFEED9802985) on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ABEO.US](https://longbridge.com/en/quote/ABEO.US.md)

## Related News & Research

- [Abeona Therapeutics Q2 2026 Earnings Call Transcript](https://longbridge.com/en/news/295818848.md)
- [Abeona Therapeutics Q2 net loss widens, misses analyst expectations](https://longbridge.com/en/news/295791975.md)
- [Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy](https://longbridge.com/en/news/296478943.md)
- [13:27 ETPatients Representing the Power of Advanced Therapies to Take Center Stage at Emily Whitehead Foundation's 2026 Believe Ball](https://longbridge.com/en/news/297074492.md)
- [Novogenia launches MGT Plus methylation genetic test in US market](https://longbridge.com/en/news/296876844.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**